Search Within

Pallawi Torka

Formats
  1. Meeting Abstract (43)
  2. Journal Article (14)
  3. Research Letter (3)
  4. Correspondence (2)
  5. Editorial (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Lymphoma (31)
  5. Hematology-Oncology Fellows (29)
  6. Sloan Kettering Institute Postdocs (28)

More Groups

People
  1. Paul Hamlin (30)
  2. Anita Kumar (28)
  3. Paola Ghione (28)
  4. Andrew Zelenetz (27)
  5. Gilles Salles (27)
  6. Lorenzo Falchi (27)

More People

Years
  1. 2025 (10)
  2. 2024 (27)
  3. 2023 (27)
Publications
  1. Blood (39)
  2. Blood Cancer Journal (4)
  3. Hematological Oncology (4)
  4. Blood Advances (3)
  5. Clinical Lymphoma, Myeloma and Leukemia (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (42)
  2. Elsevier Inc. (4)
  3. Nature Publishing Group (4)
  4. Wiley Blackwell (4)
  5. Biomed Central Ltd (3)
  6. American Society of Clinical Oncology (2)

More Publishers

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • End-of-life care patterns in older patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting
    Meeting Abstract

    Hamlin, P. A.; Torka, P.; Hansen, E.; Belli, A. J.; Ambrose, J.; Zettler, C. M.; Fernandes, L. L.; Wiley, S.; Perry, B.; Wang, C. K.
    Blood (2024)

    Fulltext@MSK | Save
  • A healthcare utilization model comparing time toxicity between glofitamab and epcoritamab
    Meeting Abstract

    Torka, P.; Masaquel, A.; Cassoli, L.; Fox, D.; Mangalindan, A.; Major, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Evaluation of risk factors for histological transformation in patients with marginal zone lymphoma (MZL): Results from a multicenter cohort study
    Meeting Abstract

    Epperla, N.; Grover, N.; Torka, P.; Karmali, R.; Annunzio, K.; Watkins, M. P.; Anampa-Guzmán, A. C.; Reves, H.; Tavakkoli, M.; Christian, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save